Edition:
United Kingdom

Penumbra Inc (PEN.N)

PEN.N on New York Stock Exchange

134.66USD
3:58pm BST
Change (% chg)

$-2.14 (-1.56%)
Prev Close
$136.80
Open
$134.07
Day's High
$136.35
Day's Low
$133.70
Volume
4,545
Avg. Vol
91,785
52-wk High
$167.30
52-wk Low
$82.65

Latest Key Developments (Source: Significant Developments)

Penumbra Inc Sees FY 2018 Revenue $400 Mln To $405 Mln
Tuesday, 27 Feb 2018 

Feb 27 (Reuters) - Penumbra Inc ::PENUMBRA, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 REVENUE $96.1 MILLION VERSUS $73.1 MILLION.SEES FY 2018 REVENUE $400 MILLION TO $405 MILLION.QTRLY EARNINGS PER SHARE ‍$0.25​.  Full Article

Penumbra Announces Formation of Joint Venture, MVI Health
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Penumbra Inc ::PENUMBRA ANNOUNCES THE FORMATION OF JOINT VENTURE, MVI HEALTH.PENUMBRA - ENTERED INTO JOINT VENTURE CALLED MVI HEALTH INC. WITH SIXENSE ENTERPRISES, INC.  Full Article

Penumbra posts Q3 revenue of $83.9 million
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Penumbra Inc :Penumbra, Inc. reports third quarter 2017 financial results.Q3 revenue $83.9 million versus I/B/E/S view $79.2 million.Sees FY 2017 revenue $324 million to $326 million.Qtrly earnings per share ‍$0.01​.  Full Article

Penumbra Q2 loss per share $0.05
Tuesday, 8 Aug 2017 

Aug 8 (Reuters) - Penumbra Inc :Penumbra Inc reports second quarter 2017 financial results.Q2 revenue $80.6 million versus I/B/E/S view $77.2 million.Qtrly net loss per share $0.05.  Full Article

Penumbra's voluntary field removal of its 3D revascularization devices will not impact its revenue guidance
Tuesday, 13 Jun 2017 

June 13 (Reuters) - Penumbra Inc -:On June 9, co initiated a voluntary field removal of four lots of its 3D revascularization devices - SEC filing.Voluntary field removal was based on company's identification of an issue involving a raw material component of the devices.Penumbra Inc - does not currently expect that this voluntary action will have material impact on its previously issued revenue guidance - sec filing.The four lots of its 3d revascularization devices were distributed between May 15, 2017 and June 7, 2017.  Full Article

Penumbra reports first quarter 2017 financial results
Tuesday, 9 May 2017 

May 9 (Reuters) - Penumbra Inc ::Penumbra inc - qtrly loss per share $0.10.Q1 earnings per share view $-0.05, revenue view $71.1 million -- Thomson Reuters I/B/E/S.Reports first quarter 2017 financial results.Q1 revenue $73.2 million versus I/B/E/S view $71.1 million.  Full Article

Penumbra announces pricing of offering of 1.3 mln shares of its common stock
Friday, 17 Mar 2017 

Penumbra Inc : Penumbra, inc. Announces pricing of offering of 1,300,000 shares of its common stock .Penumbra inc - announced pricing of an underwritten public offering of 1,300,000 shares of its common stock at a price to public of $76.00 per share.  Full Article

Penumbra launches offering of 1.3 mln shares of common stock
Wednesday, 15 Mar 2017 

Penumbra Inc : Penumbra Inc announces launch of offering of 1,300,000 shares of its common stock .Penumbra - intends to use net proceeds from this offering for general corporate purposes, including working capital, continued development of products.  Full Article

Penumbra Q4 loss per share $0.08
Tuesday, 28 Feb 2017 

Penumbra Inc : Qtrly loss per share $0.08 . Q4 earnings per share view $-0.09, revenue view $67.5 million -- Thomson Reuters I/B/E/S . FY2017 revenue view $315.4 million -- Thomson Reuters I/B/E/S . Penumbra Inc reports fourth quarter and full year 2016 financial results . Q4 revenue $73.1 million versus I/B/E/S view $67.5 million .Sees FY 2017 revenue $312 million to $317 million.  Full Article

Penumbra reports results of the ASTER Trial
Wednesday, 22 Feb 2017 

Penumbra Inc : Independent study supports use of Penumbra aspiration as frontline thrombectomy therapy for acute ischemic stroke . 85.4 percent of patients treated with Penumbra's aspiration system achieved primary endpoint of TICI 2b/3 at end of procedure .63% patients treated with aspiration system achieved secondary endpoint of TICI 2b/3 after frontline treatment versus 67.7% with stent retrievers.  Full Article

UPDATE 2-Diamondback to buy Energen in $9.2 bln deal to boost Permian presence

Aug 14 U.S. oil and gas producer Diamondback Energy Inc on Tuesday agreed to buy shale rival Energen Corp in an all-stock deal valued at $9.2 billion, giving it an expanded footprint in the country's largest and fastest growing oil field.